Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 trial is to evaluate the safety, tolerability, and pharmacokinetics of the oral formulation of CC8464 for the treatment of pain

Next Previous
X
Search
Trial Profile

A phase 1 trial is to evaluate the safety, tolerability, and pharmacokinetics of the oral formulation of CC8464 for the treatment of pain

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CC 8464 (Primary)
  • Indications Neuropathic pain
  • Focus Adverse reactions

    • Most Recent Events

    • 21 Nov 2024 According to Chromocell Corporation media release, Chromocell Corporation has changed its name to Channel Therapeutics Corporation.
    • 09 Apr 2024 Status changed to completed, according to a Chromocell Corporation media release
    • 27 Jun 2017 According to a Chromocell Corporation media release, the company received an additional milestone payment from Astellas Pharmaceuticals Inc. for the initiation of the multiple ascending dose portion of this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top